Department of Surgical oncology, Hiroshima University Hospital, Hiroshima, Japan.
Jpn J Clin Oncol. 2020 Oct 22;50(11):1306-1312. doi: 10.1093/jjco/hyaa167.
This study aimed to determine the characteristics, ground glass opacity ratio and prognosis of patients with clinical N0 non-small cell lung cancer tumours exceeding 30 mm in size.
Patients with clinical N0 non-small cell lung cancer and total tumour size >30 mm on preoperative computed tomography who underwent complete resection with lobectomy between January 2007 and December 2017 were included. The patients were divided into three groups: pure solid tumour, low ground glass opacity ratio (1-39%) tumour and high ground glass opacity ratio (≥40%) tumour. The cut-off line was determined based on the recurrence rate for every 10% ground glass opacity ratio.
Among the 227 study patients, 129 (56.8%) had a pure solid tumour, 54 (23.8%) had a low ground glass opacity ratio tumour and 44 (19.4%) had a high ground glass opacity ratio tumour. Three-year recurrence-free survival was significantly shorter in patients with a pure solid tumour (57.4%) than in patients with a low ground glass opacity ratio (74.5%; P = 0.009) or a high ground glass opacity ratio tumour (92.1%; P < 0.001). Multivariable analysis showed that ground glass opacity ratio was a significant independent prognostic factor for recurrence-free survival (hazard ratio, 0.175; P = 0.037).
Pure solid tumours comprised a large proportion of non-small cell lung cancer tumours >30 mm in size and their prognosis was poor. The presence of ground glass opacity and their relative proportion affect prognosis in patients with clinical N0 non-small cell lung cancer tumours >30 mm in size, similar to those with small-sized tumours.
本研究旨在确定肿瘤最大径>30mm 的临床 N0 非小细胞肺癌患者的特征、磨玻璃密度比(GGO 比率)及预后。
纳入 2007 年 1 月至 2017 年 12 月行完全性肺叶切除术的术前 CT 示肿瘤最大径>30mm 的临床 N0 非小细胞肺癌患者,根据肿瘤组织是否全部为实性成分,分为纯实性肿瘤、GGO 比率低(1%-39%)肿瘤及 GGO 比率高(≥40%)肿瘤三组。以每 10%GGO 比率为间隔,绘制 GGO 比率与复发率的关系曲线,确定复发风险转折点。
227 例患者中,纯实性肿瘤 129 例(56.8%),GGO 比率低肿瘤 54 例(23.8%),GGO 比率高肿瘤 44 例(19.4%)。纯实性肿瘤组患者 3 年无复发生存率(57.4%)显著低于 GGO 比率低肿瘤组(74.5%,P=0.009)及 GGO 比率高肿瘤组(92.1%,P<0.001)。多因素分析显示,GGO 比率是无复发生存的独立预后因素(风险比 0.175,P=0.037)。
肿瘤最大径>30mm 的非小细胞肺癌患者中,纯实性肿瘤占较大比例,且预后不良。GGO 存在及其相对比例影响临床 N0 非小细胞肺癌肿瘤最大径>30mm 患者的预后,与肿瘤较小者相似。